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Self-oligomerization regulates stability of survival 
motor neuron protein isoforms by sequestering 
an SCFSlmb degron
ABSTRACT Spinal muscular atrophy (SMA) is caused by homozygous mutations in hu-
man SMN1. Expression of a duplicate gene (SMN2) primarily results in skipping of exon 7 and 
production of an unstable protein isoform, SMNΔ7. Although SMN2 exon skipping is the 
principal contributor to SMA severity, mechanisms governing stability of survival motor 
neuron (SMN) isoforms are poorly understood. We used a Drosophila model system and 
label-free proteomics to identify the SCFSlmb ubiquitin E3 ligase complex as a novel SMN 
binding partner. SCFSlmb interacts with a phosphor degron embedded within the human and 
fruitfly SMN YG-box oligomerization domains. Substitution of a conserved serine (S270A) 
interferes with SCFSlmb binding and stabilizes SMNΔ7. SMA-causing missense mutations that 
block multimerization of full-length SMN are also stabilized in the degron mutant back-
ground. Overexpression of SMNΔ7S270A, but not wild-type (WT) SMNΔ7, provides a protec-
tive effect in SMA model mice and human motor neuron cell culture systems. Our findings 
support a model wherein the degron is exposed when SMN is monomeric and sequestered 
when SMN forms higher-order multimers.
INTRODUCTION
Spinal muscular atrophy (SMA) is a common neuromuscular disor-
der, recognized as the most prevalent genetic cause of early child-
hood mortality (Pearn, 1980). Patients with the most severe form of 
the disease, which is also the most common, become symptomatic 
in the first 6 mo of life and rarely live past 2 yr (Prior, 2010; Wee 
et al., 2010). Because the onset of symptoms and their severity can 
vary, SMA has historically been classified into three subtypes (Ogino 
and Wilson, 2004). More recently, clinicians have recognized that 
SMA is better characterized as a continuous spectrum disorder, 
ranging from acute (prenatal onset) to nearly asymptomatic (Tiziano 
et al., 2013). Clinically, SMA patients experience degeneration of 
motor neurons in the anterior horn of the lower spinal cord (Crawford 
and Pardo, 1996). This leads to progressive atrophy of proximal 
muscle groups, ultimately resulting in loss of motor function and 
symmetrical paralysis. The cause of death is often restrictive respira-
tory failure (Kolb and Kissell, 2015).
SMA typically results from homozygous deletion of the survival 
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et al., 2012). Although it is highly similar to human SMN1 and SMN2, 
the entire open reading frame of fruitfly Smn is contained within a 
single exon, and so only full-length SMN protein is expressed in 
Drosophila (Rajendra et al., 2007). When modeled in the fly, SMA-
causing point mutations recapitulate the full range of phenotypic 
severity seen in humans (Praveen et al., 2014; Garcia et al., 2016). 
Using this system, we carried out proteomic profiling of Flag-puri-
fied embryonic lysates and identified the SCFSlmb E3 ubiquitin ligase 
complex as a novel SMN interactor. Importantly, this interaction 
is conserved from flies to humans. We show that SCFSlmb binding 
requires a phosphodegron motif located within the SMN self-oligo-
merization domain, mutation of which stabilizes SMN∆7 and, to a 
lesser extent, full-length SMN. Additional studies in flies, mice, and 
human cells elucidate a disease-relevant mechanism whereby 
SMN protein stability is regulated by self-oligomerization. Other E3 
ligases have been reported to target SMN for degradation in 
cultured human cells (Hsu et al., 2010; Kwon et al., 2013; Han et al., 
2016). Given our findings in fruit-fly embryos, SMN is likely targeted 
by multiple E3 ubiquitin ligases.
RESULTS
Flag-SMN interacts with ubiquitin proteasome system 
proteins
We previously generated transgenic flies that express Flag-tagged 
SMN proteins in an otherwise null Smn background (Praveen et al., 
2012). To preserve endogenous expression patterns, the constructs 
are driven by the native promoter and flanking sequences. As de-
scribed under Materials and Methods, we intercrossed hemizygous 
Flag-SmnWT,SmnX7/SmnD animals to establish a stock wherein all of 
the SMN protein, including the maternal contribution, is epitope 
tagged. After breeding them for >100 generations, essentially all of 
the animals are homozygous for the Flag-SmnWT transgene, but 
second-site recessive mutations are minimized due to the use of two 
different Smn null alleles. Adults from this stock display no apparent 
defects and have an eclosion frequency (∼90%) similar to that of 
wild-type (Oregon-R) animals.
We collected (0–12 h) embryos from Flag-SmnWT/WT,SmnX7/D 
(SMN) and Oregon-R (Ctrl) animals and analyzed Flag-purified 
lysates by “label-free” mass spectrometry. In addition to Flag-SMN, 
we identified SMN complex components Gemin2 and Gemin3, 
along with all seven of the canonical Sm-core snRNP proteins (Figure 
1A). We also identified the U7-specific Sm-like heterodimer 
Lsm10/11 (Pillai et al., 2003) and the Gemin5 orthologue, Rigor 
mortis (Gates et al., 2004). Previous studies of Schneider2 (S2) cells 
transfected with epitope-tagged Smn had identified most of the 
proteins listed above as SMN binding partners in Drosophila (Kroiss 
et al., 2008). However, despite bioinformatic and cell biological data 
indicating that Rigor mortis is part of the fruit-fly SMN complex, this 
protein failed to copurify with SMN in S2 cells (Kroiss et al., 2008; 
Cauchi et al., 2010; Guruharsha et al., 2011). On the basis of our 
purification data, we conclude that the conditions are effective and 
that Rigor mortis/Gemin5 is an integral member of the SMN 
complex in flies.
A detailed proteomic analysis of these flies will be presented 
elsewhere. As shown in Figure 1B, our preliminary analysis identified 
396 proteins, 114 of which were detected only in the Flag-SMN 
sample and not in the control. An additional 279 proteins were de-
tected in both the Flag purification and control samples. In addition 
to SMN complex members, we copurified numerous factors that are 
part of the ubiquitin proteasome system (UPS; Figure 1C). Among 
these UPS proteins, we identified Cullin 1 (Cul1), Skp1-related A 
(SkpA), and supernumerary limbs (Slmb), as being highly enriched 
of SMA patients have lost one copy of SMN1 and the remaining 
copy contains a point mutation (Burghes and Beattie, 2009). Humans 
have two SMN paralogues, named SMN1 and SMN2, both of which 
contribute to total cellular levels of survival motor neuron (SMN) 
protein. SMN2 exon 7 contains a silent base change that alters splic-
ing to primarily produce a truncated, unstable protein product 
called SMN∆7 (Lorson et al., 1999; Monani et al., 1999; Lorson and 
Androphy, 2000). The last 16 amino acids of SMN are replaced in 
SMN∆7 by four amino acids, EMLA, encoded by exon 8. Current 
estimates suggest that SMN2 produces 10–15% of the level of full-
length protein produced by SMN1 (Lorson et al., 2010). Complete 
loss of SMN is lethal in all organisms investigated to date (O’Hearn 
et al., 2016). Although the amount of full-length protein produced 
by SMN2 is not enough to compensate for loss of SMN1, SMN2 is 
sufficient to rescue embryonic lethality (Monani et al., 2000). SMA is 
therefore a disease that arises due to a hypomorphic reduction in 
SMN levels (Lefebvre et al., 1995). Furthermore, relative levels of 
the SMN protein correlate with the phenotypic severity of SMA 
(Coovert et al., 1997; Lefebvre et al., 1997).
Whereas a causative link between SMN1 and SMA was estab-
lished in the early 1990s, the molecular role of SMN in disease etiol-
ogy remains unclear. SMN is the central component of a multimeric 
protein assemblage known as the SMN complex (Li et al., 2014; 
Matera and Wang, 2014). The best-characterized function of this 
complex, which is found in all tissues of metazoan organisms, is in 
the cytoplasmic assembly of small nuclear ribonucleoproteins 
(snRNPs), core components of the spliceosome (Fischer et al., 1997; 
Meister et al., 2001; Pellizzoni et al., 2002).
Although it is ubiquitously expressed, SMN has also been impli-
cated in a number of tissue-specific processes related to neurons 
and muscles. These functions include actin dynamics (Oprea et al., 
2008; Ackermann et al., 2013), axonal pathfinding (Fan and Simard, 
2002; McWhorter et al., 2003; Sharma et al., 2005), axonal transport 
of β-actin mRNP (Rossoll et al., 2003), phosphatase and tensin ho-
molog-mediated (PTEN-mediated) protein synthesis pathways 
(Ning et al., 2010), translational regulation (Sanchez et al., 2013), 
neuromuscular junction formation and function (Chan et al., 2003; 
Kariya et al., 2008; Kong et al., 2009; Voigt et al., 2010), myoblast 
fusion (Shafey et al., 2005), and maintenance of muscle architecture 
(Rajendra et al., 2007; Walker et al., 2008; Bowerman et al., 2009).
Ubiquitylation pathways have been shown to regulate the stabil-
ity and degradation of SMN (Chang et al., 2004; Burnett et al., 2009; 
Hsu et al., 2010) as well as axonal and synaptic stability (Korhonen 
and Lindholm, 2004). In the ubiquitin proteasome system (UPS), 
proteins destined for degradation are tagged by linkage to ubiqui-
tin through the action of three factors (Petroski, 2008). E1 proteins 
activate ubiquitin and transfer it to the E2 enzyme. E2 proteins 
conjugate ubiquitin to their substrates. E3 proteins recognize the 
substrate and assist in the transfer of ubiquitin from the E2. Because 
E3 ligases confer substrate specificity, they are typically considered 
as candidates for targeted inhibition of protein degradation. Ubiq-
uitin homeostasis is thought to be particularly important for neuro-
muscular pathology in SMA (Groen and Gillingwater, 2015). Indeed, 
mouse models of SMA display widespread perturbations in UBA1 
(ubiquitin-like modifier activating enzyme 1) levels (Wishart et al., 
2014). Furthermore, mutations in UBA1 are known to cause X-linked 
infantile SMA (Ramser et al., 2008; Schmutzler et al., 2008).
Given the importance of these processes to normal develop-
ment as well as neurodegenerative disease, we set out to identify 
and characterize novel SMN binding partners. Previously, we devel-
oped Drosophila melanogaster as a model system wherein the en-
dogenous Smn gene is replaced with a Flag-Smn transgene (Praveen 
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1998). SkpA is a bridging protein essential 
for interaction of Cul1 with the F-box pro-
tein (Patton et al., 1998a,b). Because of its 
role in substrate recognition, Slmb is likely 
to be the direct interacting partner of SMN 
within the SCFSlmb complex. For this reason, 
we focused on Slmb for the initial validation. 
As shown, Slmb was easily detectable in 
Flag-purified eluates from embryos express-
ing Flag-SMN and nearly undetectable in 
those from control embryos (Figure 1D). 
SmB and SmD3 were also easily detectable 
by Western blot in Flag-purified embryonic 
lysates and were used as positive controls 
for known protein interaction partners of 
SMN. Tubulin and α-actinin were not de-
tected as interacting with SMN in our purifi-
cation and demonstrate the specificity of 
the detected SMN interactions.
SCFSlmb is a bona fide SMN interaction 
partner that ubiquitylates SMN
As an E3 ubiquitin ligase, the SCFSlmb com-
plex is a substrate recognition component 
of the ubiquitin proteasome system. As out-
lined in Figure 2A, E3 ligases work with E1 
and E2 proteins to ubiquitylate their targets. 
The interaction of SCFSlmb with SMN was 
verified in a reciprocal coimmunoprecipita-
tion, demonstrating that Flag-tagged SCF 
components form complexes with endoge-
nous SMN (Figure 2B) in S2 cells.
SCF complexes are highly conserved 
from flies to humans: SkpA is 77% identical 
to human Skp1, Cul1 is 63% identical, and 
Slmb is 80% identical to its human homo-
logues, B-TrCP1 and B-TrCP2. Slmb/B-TrCP 
is the SCF component that directly contacts 
substrates of the E3 ligase. We therefore 
tested the interaction of recombinant hu-
man SMN in complex with (SMN•Gem2) 
Gupta et al., 2015) with GST-tagged B-
TrCP1 and -SMN proteins in an in vitro 
binding assay. As shown in Figure 2C, 
SMN•Gem2 did not interact with GST alone 
but was detected at high levels following 
pull down with either GST-SMN (positive 
control) or GST-B-TrCP1. We also tested the 
interaction of Flag-tagged Drosophila SCF 
components with endogenous human SMN 
in HEK 293T cells (Figure 2D). Accordingly, 
human SMN was coprecipitated with Flag-
Cul1 and Flag-Slmb and at lower levels 
following Flag-SkpA immunoprecipitation. 
Flag-B-TrCP1 and Flag-B-TrCP2, the two hu-
man homologues of Slmb, also copurified 
with endogenous human SMN in HEK 293T 
cells (Figure 2E). Altogether, these data demonstrate a conserved 
interaction between SMN and the SCFSlmb/B-TrCP E3 ubiquitin ligase 
complex.
To test the functional consequences of this conserved interaction 
between SMN and SCFSlmb/B-TrCP, a cell-based ubiquitylation assay 
[AQ 2]
FIGURE 1: Flag-SMN immunopurified lysates contain known protein interaction partners and 
ubiquitin proteasome system (UPS) proteins. (A) Lysates from Oregon-R control (Ctrl) Drosophila 
embryos and embryos expressing only transgenic Flag-SMN (SMN) were Flag-immunopurified, 
and protein eluates were separated by gel electrophoresis and silver stained. Band identities 
predicted by size using information from panels C and D. (B) Direct mass spectrometric analysis 
of the eluates (which were not gel purified) identified a total of 396 proteins, 114 of which were 
detected only in SMN sample and 279 of which were detected in both SMN and Ctrl samples. 
(C) Flag-purified eluates were analyzed by “label-free” mass spectrometry. Numerous proteins 
that copurify with Flag-SMN are part of the ubiquitin proteasome system (UPS). Of these UPS 
proteins, Cullin 1 (Cul 1), SkpA, and supernumerary limbs (Slmb) were highly enriched (at least 
10-fold) in the SMN sample as compared with Ctrl. (D) Western blot analysis of Flag-purified 
eluates was used to further validate the presence or absence of SMN interaction partners. 
Flag-SMN was successfully purified from SMN embryos but was undetectable in the control. As 
positive controls for known protein interaction partners of SMN, SmB and SmD3 were also easily 
detectable by Western blotting using anti-Sm antibodies. The presence of Slmb was verified 
using anti-Slmb. α-Actinin and tubulin were not enriched in our purification and are used as 
negative controls to demonstrate specificity.
(>10-fold) in Flag-SMN samples as compared with the control. To-
gether, these proteins comprise the SCFSlmb E3 ubiquitin ligase. 
Cul1 forms the major structural scaffold of this horseshoe-shaped, 
multisubunit complex (Zheng et al., 2002). Slmb is an F-box protein 
and is the substrate recognition component (Jiang and Struhl, 
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FIGURE 2: Conserved interaction between SMN and the SCFSlmb/B-TrCP E3 ubiquitin ligase results in ubiquitylation of 
SMN. (A) E3 ligases work with E1 and E2 proteins to ubiquitylate their targets. The SCFSlmb/B-TrCP E3 ubiquitin ligase is 
made up of three proteins: Cul1, SkpA, and Slmb. The E3 ubiquitin ligase is the substrate recognition component of the 
ubiquitin proteasome system. (B) Following Cul1-Flag, SkpA-Flag, Flag-Slmb, and Flag-Gem2 immunoprecipitation from 
Drosophila S2 cell lysates, Western analysis using anti-SMN antibody for endogenous SMN was carried out. 
Copurification of each of the SCF components with endogenous SMN was detected. (C) An in vitro binding assay tested 
direct interaction between human SMN∆5-Gemin2 (SMN•Gem2) (Martin et al., 2012; Gupta et al., 2015) and purified 
GST-tagged proteins. SMN•Gem2 did not interact with GST protein alone but bound to GST tagged Drosophila SMN 
(GST-SMN) and GST tagged human B-TrCP1 (GST-B-TrCP1). Levels of GST alone, GST-SMN, and GST-B-TrCP1 were 
detected using anti-GST antibody. (D) The interaction of Flag-tagged Drosophila SCF components with endogenous 
human SMN was tested in in HEK 293T cells. Human SMN was detected at high levels following immunoprecipitation of 
Drosophila Flag-Cul1 and Flag-Slmb and detected at a lower level following Drosophila Flag-SkpA immunoprecipitation. 
(E) Flag-tagged versions of the human homologues of Slmb, Flag-B-TrCP1, and Flag-B-TrCP2, interact with endogenous 
human SMN in HEK 293T cells demonstrated by Flag-immunopurification followed by immunodetection of SMN. 
(F) Protein lysate from HEK 293T cells transfected with 6xHis-Flag-ubiquitin (6HF-Ub) and GFP-SMN was purified using a 
Ni2+ pull down for the tagged ubiquitin. Baseline levels of ubiquitylated GFP-SMN were detected using anti-GFP 
antibody. Following transfection of Flag-B-TrCP1 or Flag-B-TrCP2, the levels of ubiquitylated SMN markedly increased. 
Ubiquitylation levels were further increased following addition of both proteins together. In the input, GFP-SMN was 
detected using anti-GFP antibody, Flag-B-TrCP1 and Flag-B-TrCP2 were detected using anti-Flag antibody, and GAPDH 
was detected by anti-GAPDH antibody. In the Ni2+ pull down, ubiquitylated GFP-SMN was detected using anti-GFP 
antibody and 6HF-Ub was detected using anti-Flag antibody to verify successful pull down of tagged ubiquitin.
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These experiments demonstrate that SCFSlmb/B-TrCP can ubiquitylate 
SMN in vivo.
Depletion of Slmb/B-TrCP results in a modest increase in 
SMN levels
Given that one of the primary functions of protein ubiquitylation is 
to target proteins to the proteasome, we examined whether deple-
tion of Slmb by RNA interference (RNAi) us-
ing dsRNA in S2 cells would increase SMN 
levels (Figure 3A). Following Slmb RNAi, 
endogenous SMN levels were modestly in-
creased as compared with cells treated with 
control dsRNA. We obtained similar results 
using an siRNA that targets both B-TrCP1 
and B-TrCP2 in HeLa cells. As shown in 
Figure 3B, we detected a modest increase 
in levels of full-length SMN following B-TrCP 
RNAi but not control RNAi. Next, we treated 
S2 cells with cycloheximide (CHX), in the 
presence or absence of dsRNA targeting 
Slmb, to determine whether differences in 
SMN levels would be exacerbated when 
production of new proteins was prevented 
(Figure 3C). SMN protein levels were also 
specifically targeted using dsRNA against 
Smn as a positive control for the RNAi treat-
ment. At 6 h post–CHX treatment, there was 
a modest increase in full-length SMN levels 
following Slmb RNAi as compared with the 
initial timepoint (0 h) or the negative control 
(Ctrl) RNAi (Figure 3C). Together, these data 
indicate that Slmb/B-TrCP participates in 
the regulation of SMN protein levels.
Identification and characterization of a 
Slmb/B-TrCP degradation signal in 
SMN
Studies of numerous UPS substrates in a vari-
ety of species have revealed the presence of 
degradation signals (called degrons) that are 
required for proper E3 target recognition 
and binding. Slmb/B-TrCP canonically recog-
nizes a consensus DpSGXXpS/T degron, 
where p indicates a phosphoryl group (Fuchs 
et al., 2004; Jin et al., 2005; Frescas and 
Pagano, 2008). There are also several known 
variants of this motif, for example, DDGFVD, 
SSGYFS, and TSGCSS (Kim et al., 2015). As 
shown in Figure 4A, we identified a putative 
Slmb/B-TrCP degron (269MSGYHT274) in the 
highly conserved self-oligomerization do-
main (YG Box) of human SMN. Interestingly, 
this sequence was previously identified as 
part of a larger degron motif (268YMSGYHT-
GYYMEMLA282) that was thought to be 
created in SMN∆7 by SMN2 alternative splic-
ing (Cho and Dreyfuss, 2010). In particular, 
mutation of S270 (S201 in flies) to alanine 
was shown to dramatically stabilize SMN∆7 
constructs in human cells, and overex-
pression of SMN∆7S270A in SMN-deficient 
chicken DT40 cells rescued their viability 
[AQ 3]
was performed (Figure 2F). Protein lysate from HEK 293T cells trans-
fected with 6xHis-Flag-ubiquitin and GFP-SMN was purified using a 
Ni2+ pull down for the tagged ubiquitin. Baseline levels of ubiquity-
lated GFP-SMN were detected using anti-GFP antibody. Following 
transfection of Flag-B-TrCP1 or Flag-B-TrCP2, the levels of ubiquity-
lated SMN markedly increased (Figure 2F). Ubiquitylation levels 
were further increased following addition of both proteins together. 
FIGURE 3: Depletion of Slmb/B-TrCP results in an increase of SMN levels. (A) Depletion of Slmb 
using 10-d (10d) treatment with dsRNA in Drosophila S2 cells resulted in modestly increased 
SMN levels. Following Slmb RNAi, full-length SMN levels were increased as compared with 
cells treated with control dsRNA against Gaussia Luciferase, which is not expressed in S2 cells. 
(B) The effect of B-TrCP depletion on SMN levels in human cells was tested using siRNA that 
targets both B-TrCP1 and B-TrCP2 in HeLa cells. We detected a modest increase in levels of 
full-length endogenous SMN after B-TrCP RNAi but not control (scramble) RNAi. (C) Drosophila 
S2 cells were treated with cycloheximide (CHX), an inhibitor of protein synthesis, following Slmb 
depletion following a 3-d dsRNA treatment to test whether differences in protein levels would 
be exacerbated when the production of new protein was prevented. SMN protein levels were 
also directly targeted using dsRNA against Smn as a positive control for the RNAi treatment. As 
a negative control (Ctrl), dsRNA against oskar, which is not expressed in S2 cells, was used. 
Protein was collected at 0, 2, and 6 h post–CHX treatment. At 6 h post–CHX treatment, there is 
a modest increase in full-length SMN levels following Slmb RNAi as compared with the initial 
time point (0 h) and as compared with control RNAi treatment.
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(Cho and Dreyfuss, 2010). However, factors 
responsible for specifically mediating SMN∆7 
degradation have not been identified.
To develop a more disease-relevant 
Drosophila system to investigate SMN YG 
box function, we generated a “vertebrate-
like” SMN construct, called vSmn (Figure 
4A). Transgenic flies expressing Flag-vSmn 
and Flag-vSmnS201A in the background of an 
SmnX7 null mutation are fully viable (Supple-
mental Figure S1). In fact, the eclosion 
frequencies of these animals are consis-
tently higher than those that express Flag-
SmnWT (Supplemental Figure S1). Additional 
Smn mutant constructs were generated us-
ing the vSmn backbone, including both the 
full-length (e.g., vSmnS201A) and truncated 
(e.g., vSmn∆7A) versions of the protein 
(Figure 4A). To test the effects of overall 
protein length and distance of the putative 
degron from the C-terminus, we also gener-
ated vSmn constructs that are the same 
length as SMN∆7, replacing the MEMLA* 
motif (the amino acids introduced by human 
SMN2 splicing) with MGLRQ*; see Figure 
4A. The S201A mutation was created in this 
construct as well (MGLRQ*S201A). To mimic a 
constitutively phosphorylated state, we also 
introduced serine to aspartate mutations, 
vSmnS201D and vSmn∆7D. We transfected 
each of these constructs, Flag-tagged and 
driven by the native Smn promoter, into S2 
cells and measured protein levels by West-
ern blotting (Figure 4B). We note that these 
constructs are expressed at levels far below 
those of endogenous SMN protein in S2 
cells; moreover, they do not affect levels of 
endogenous SMN (Supplemental Figure 
S2). As shown, the vSmnS201A and vSMN∆7A 
constructs exhibited increased protein lev-
els compared with their serine containing 
counterparts, whereas levels of the S201D 
mutants were reduced, suggesting that the 
phosphodegron motif identified in human 
SMN∆7 (Cho and Dreyfuss, 2010) is also 
conserved in the fly protein. In addition to 
examining protein levels of each of these 
constructs in cell culture, transgenic flies ex-
pressing vSmn, vSmnS201A, vSmn∆7S, and 
vSmn∆7A were created. Here again, we ob-
served that the S201A mutation increased 
protein levels of both full-length SMN and 
SMN∆7 (Supplemental Figure S3).
FIGURE 4: Identification and mutation of a putative Slmb/B-TrCP phosphodegron 
(A) Identification of a conserved putative Slmb phosphodegron (DpSGXXpS/T motif variant) in 
the C-terminal self-oligomerization domain (YG Box) of SMN. The amino acid sequence of SMN 
from a variety of vertebrates is shown to illustrate conservation of this motif and rationale for 
the amino acid changes. Full-length human SMN is labeled as “Human,” and the truncated 
isoform is labeled “hSMN∆7.” Endogenous D. melanogaster SMN is labeled “Fruitfly.” To 
generate a more vertebrate-like SMN, key amino acids in Drosophila SMN were changed to 
amino acids conserved in vertebrates. Using this SMN backbone, a serine-to-alanine mutation 
was made in the putative degron in both full-length (vSMNS201A) and truncated SMN∆7 
(vSMN∆7A). An additional SMN construct that is the same length as SMN∆7, but has the amino 
acid sequence GLRQ (the next amino acids in the sequence) rather than EMLA (the amino acids 
introduced by mis-splicing of SMN2), was generated. The same serine to alanine mutation was 
made in this construct as well (MGLRQ* and MGLRQ*S201A). Finally, to mimic a phosphorylated 
serine, a full-length vSmnS201D and truncated vSmn∆7D were also employed. (B) Western blotting 
was used to determine protein levels of each of these SMN constructs, with expression driven 
by the endogenous promoter, in Drosophila S2 cells. Both the vSMN and vSMN∆7S proteins 
show increased levels when the serine is mutated to an alanine, indicating disruption of the 
normal degradation of SMN. Additionally, MGLRQ* protein is present at higher levels than is 
vSMN∆7S and protein levels do not change when the serine is mutated to an alanine. 
Normalized fold change as compared with vSmn levels is indicated at the bottom. *p < 0.05, 
**p < 0.01, n = 3. (C) Flag-tagged SMN constructs were cotransfected with Myc-Slmb in 
Drosophila S2 cells. Protein lysates were Flag-immunoprecipitated and probed with anti-Myc 
antibody to detect SMN-Slmb interaction. In both full-length SMN (vSMN) and truncated SMN 
(vSMN∆7), serine-to-alanine mutation decreased interaction of Slmb with SMN. Truncated SMN 
(vSMN∆7) showed a dramatically increased interaction with Slmb as compared with full-length 
SMN (vSMN), despite the fact it is present at lower levels. (D) Full-length SMN constructs 
containing point mutations known to decrease self-oligomerization (SmnY203C and SmnG206S) and 
a mutation that does not disrupt self-oligomerization in the fly (SmnG210V) with and without the 
serine-to-alanine mutation were transfected 
in Drosophila S2 cells. The constructs 
containing the serine to alanine mutation 
are as follows: SmnY203C→Smn3C-1A, 
SmnG206S→Smn6S-1A, SmnG210V→Smn10V-1A. The 
serine to alanine mutation has a stabilizing 
effect on SMN mutants with poor self-
oligomerization capability. *p < 0.05, n = 3.
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The MGLRQ* construct is present at levels that are similar to wild 
type (vSmn) and much higher than vSmn∆7S. Based on the crystal 
structures of the SMN YG box (Martin et al., 2012; Gupta et al., 
2015), the presence of the MGLR insertion in Drosophila SMN is 
predicted to promote self-oligomerization (unpublished data), thus 
stabilizing the protein within the SMN complex (Burnett et al., 2009). 
By the same logic, the relative inability of vSmn∆7S to self-interact 
would be predicted to lead to its destruction. To determine whether 
the observed increase in SMN protein levels correlated with its 
ability to interact with Slmb, we cotransfected the appropriate 
Flag-Smn constructs with Myc-Slmb in S2 cells. Protein lysates were 
then Flag-immunoprecipitated and probed with anti-Myc antibody 
(Figure 4C). The S201A mutation decreased binding of Slmb to both 
the full-length and the truncated SMN isoforms (Figure 4C). How-
ever, the vSmn∆7S construct coprecipitated the greatest amount 
of Slmb protein, despite the fact that it is present at much lower 
levels in the input lysate (Figure 4C). Because SMN∆7 is defective in 
self-interaction, this result suggests that the degron is more acces-
sible to Slmb when SMN is monomeric and cannot efficiently 
oligomerize.
SMN self-oligomerization regulates access to the Slmb 
degron
To examine the connection between SMN self-oligomerization and 
degron accessibility more closely, we took advantage of two SMA 
patient-derived point mutations (Y203C and G206S) that are known 
to destabilize the full-length protein and to decrease its self-
oligomerization capacity (Praveen et al., 2014). As a control, we also 
employed an SMA-causing mutation (G210V) that does not disrupt 
SMN self-oligomerization (Praveen et al., 2014; Gupta et al., 2015). 
Next, we introduced the S201A degron mutation into all three of 
these full-length SMN constructs, transfected them into S2 cells and 
carried out Western blotting (Figure 4D and Supplemental Figure 
S2). The S201A degron mutation has a clear stabilizing effect on the 
G206S and Y203C constructs, as compared with the effect of S201A 
paired with G210V. Hence, we conclude that the Slmb degron is 
exposed when SMN is present predominantly as a monomer, 
whereas it is less accessible when the protein is able to form higher-
order multimers.
Mutation of the Slmb degron rescues viability and 
locomotion defects in SMA model flies
Next, we examined the effect of mutating the Slmb degron in the 
context of the full-length protein in vivo. We characterized adult 
viability, larval locomotion, and SMN protein expression pheno-
types of the G206S mutants in the presence or absence of the de-
gron mutation, S201A (Figure 5, A–C). As described previously 
(Praveen et al., 2014), SmnG206S animals express very low levels of 
SMN and fail to develop beyond larval stages. In contrast, flies bear-
ing the S201A degron mutation in addition to G206S (Smn6S-1A) ex-
press markedly increased levels of SMN protein (Figure 5C), and a 
good fraction of these animals complete development (Figure 5A). 
Moreover, Smn6S-1A larvae display significantly improved locomotor 
activity as compared with SmnG206S or SmnX7 null mutants (Figure 5B). 
[AQ 4]
FIGURE 5: Mutation of the Slmb degron rescues defects in SMA 
model flies. (A) Viability analysis of an SMA point mutation (G206S) in 
the presence and absence of the degron mutation, S201A. Flies with 
the following genotypes were analyzed in this experiment: Oregon-R 
(Ctrl), Flag-SmnWT,SmnX7/SmnX7 (SmnWT), Flag-SmnG206S,SmnX7/SmnX7 
(SmnG206S), Flag-SmnG206,S201A,SmnX7/SmnX7 (Smn6S-1A), or SmnX7/SmnX7 
(SmnX7). The data for each genotype are expressed as a fraction of 
pupae or adults over the total number of starting larvae, n = 200. 
Expression of the WT transgene (SmnWT) shows robust rescue of the 
null (SmnX7) phenotype (∼68% adults). SmnG206S is a larval lethal 
mutation. In two independent recombinant lines of Smn6S-1A (Smn6S-1A1 
and Smn6S-1A2) a fraction of the larvae complete development to 
become adults. (B) Locomotor ability of early third-instar larvae was 
determined by tracking their movement for 1 min and then calculating 
the velocity. To account for potential differences in larval size, speed is 
expressed as average body lengths per second moved. Genotypes 
are as in panel A. SmnG206S larvae move similarly to null animals. The 
motility of Smn6S-1A1 and Smn6S-1A2 larvae is not different from Ctrl or 
SmnWT larvae. ***p < 0.001, n = 50–60 larvae. (C) Larval protein levels 
were examined by Western blotting; genotypes as in panel A. Lysates 
from hemizygous mutant lines were probed with anti-Flag or 
anti-SMN antibodies as indicated. The slower-migrating bands 
represent the Flag-tagged transgenic proteins and the faster 
migrating band corresponds to endogenous SMN, which is present 
only in the Ctrl (note Oregon-R has two copies Smn, whereas the 
transgenics have only one). SmnG206S has very low levels of SMN 
protein. Flies bearing the S201A degron mutation in addition to 
G206S (Smn6S-1A) express markedly increased levels of SMN protein.
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(Smn−/−;SMN2;SMN∆7) is a model of severe SMA (Le et al., 2005), 
and affected pups usually die between P10 and P18 (avg. = P15). 
The “2B/–“ mouse (Smn2B/–) is a model of intermediate SMA 
(Bowerman et al., 2012; Rindt et al., 2015) and these animals survive 
much longer, typically between P25 and P45 (avg. = P32). Adeno-
associated virus serotype 9 (AAV9) was selected to deliver the SMN 
cDNA isoforms to these SMA mice, as this vector has previously 
been shown to enter and express in SMA-relevant tissues and can 
dramatically rescue the SMA phenotype when expressing the wild-
type SMN cDNA (Foust et al., 2010; Passini et al., 2010; Valori et al., 
2010; Dominguez et al., 2011; Glascock et al., 2012).
Delivery of AAV9-SMN∆7A at P1 significantly extended survival 
in the intermediate 2B/– animals, resulting in 100% of the treated 
pups living beyond 100 d, similar to the results obtained with the 
full-length AAV9-SMN construct (Figure 7A). In contrast, untreated 
2B/– animals lived, on average, only 30 d. Mice treated with AAV9-
SMN∆7S survived an average of 45 d (Figure 7A). Mice treated with 
AAV9-SMN∆7D, a phosphomimetic of the wild-type serine 270 resi-
due, have an average life span that is equivalent or slightly shorter 
than that of untreated 2B/– mice (Figure 7A). These results not only 
highlight the specificity of the S270A mutation in conferring efficacy 
to SMN∆7 but also illustrate that AAV9-mediated delivery of protein 
alone does not improve the phenotype.
We also analyzed the effects of SMN∆7A expression in the se-
vere Delta7 mouse model (Le et al., 2005). Treatment with AAV9-
SMN∆7A had only a very modest effect on Delta7 mice, as none of 
the animals (treated or untreated) survived weaning (Supplemental 
Figure S4). These findings are similar to the results in Drosophila. 
Transgenic expression of SMN∆7A in the Smn null background is 
not sufficient to rescue larval lethality (Supplemental Figure S3). 
Thus expression of SMN∆7A provides a clear protective benefit to 
the viability of intermediate mice but not to severe SMA models.
Consistent with the life-span data, AAV9-SMN∆7A treated 2B/– 
mice gained significantly more weight than either untreated or AAV-
SMN∆7S-treated animals, nearly achieving the same weight as pups 
treated with full-length AAV-SMN (Figure 7B). Treatment with full-
length SMN cDNA resulted in animals that were clearly stronger and 
more mobile, consistent with the weight data (Figure 7C). Although 
they did not perform as well as mice treated with full-length SMN 
cDNA, the SMN∆7A-treated animals retained strength and gross 
motor function at late time points (e.g., P100), as measured by their 
ability to splay their legs and maintain a hanging position using a 
modified tube test, (Figure 7C). Animals treated with AAV9-SMN∆7D 
and -SMN∆7S did not survive long enough for testing.
SCFSlmb primarily targets unstable SMN monomers
As indicated in Figure 8, our findings suggest a model whereby 
SMN and SMN∆7 degradation is in part mediated by SCFSlmb, a 
multicomponent E3 ubiquitin ligase composed of Slmb, SkpA, Cul1, 
and Roc1 (Jiang and Struhl, 1998, Patton et al., 1998a,b; Zheng 
et al., 2002). Our work demonstrates that B-TrCP/Slmb binds di-
rectly to SMN (Figure 2) and is one of a growing number of E3 
ligases in the cell that can target SMN protein (Kwon et al., 2013; 
Han et al., 2016). SMN monomers, such as those created in SMN∆7, 
are the primary targets for degradation. As shown in the model, 
partially active SMN•SMN∆7 dimers and active SMN oligomers are 
also substrates but to a lesser extent.
DISCUSSION
Factors that recognize the putative SMN∆7-specific degron have not 
been identified, and the molecular mechanisms governing protea-
somal access to SMN and SMN∆7 remain unclear. In this study, we 
These results strongly suggest that both the structure of the G206S 
mutant protein as well as its instability contribute to the organismal 
phenotype.
GFP-SMNΔ7 overexpression stabilizes endogenous SMN 
and SMNΔ7 in cultured human cells
Increased SMN2 copy number correlates with a milder clinical phe-
notype in SMA patients (Oskoui et al., 2016). This phenomenon was 
successfully modeled in mice in the early 2000s (Hsieh-Li et al., 
2000; Monani et al., 2000), showing that high-copy-number SMN2 
transgenes fully rescue the null phenotype, whereas low-copy trans-
genes do not. Moreover, transgenic expression of a human SMN∆7 
cDNA construct in a low-copy SMN2 background improves survival 
of this severe SMA mouse model from P5 (postnatal day 5) to P13 
(Le et al., 2005). Although the truncated SMN likely retains partial 
functionality, the protective effect of SMN∆7 overexpression may 
not entirely be intrinsic to the protein. That is, SMN∆7 could also act 
as a “soak-off” factor, titrating the ubiquitylation machinery and sta-
bilizing endogenous SMN. In such a scenario, the prediction would 
be that SMN∆7A is less protective than SMN∆7S because it is not a 
very good substrate for SCFSlmb.
We therefore compared the stabilizing effects of overexpressing 
GFP-tagged SMN∆7S270A (SMN∆7A) and SMN∆7 (SMN∆7S) on en-
dogenous human SMN and SMN∆7. HEK 293T cells were trans-
fected with equivalent amounts of GFP-SMN∆7A or -SMN∆7S. The 
following day, cells were harvested after treatment with cyclohexi-
mide (CHX) for zero to 10 h. As shown in Figure 6A, Western blot-
ting with anti-SMN showed that the SMN∆7S construct exhibits a 
clear advantage over SMN∆7A in its ability to stabilize endogenous 
SMN and SMN∆7. By comparing band intensities within a given 
lane, we generated average intensity ratios for each time point 
using replicate blots (Figure 6A, table). We then calculated a “stabi-
lization factor” by taking a ratio of these two ratios. As shown (Figure 
6A, graph), the protective benefit of overexpressing ∆7S versus ∆7A 
at t = 0 h was roughly 3.0× for endogenous SMN∆7 and 1.75× for 
full-length SMN. Thus, as predicted above, the GFP-SMN∆7A 
construct was much less effective at stabilizing endogenous SMN 
isoforms. Because SMN∆7 is a relatively good SCFSlmb substrate, 
overexpression of this isoform protects full-length SMN from 
degradation.
As mentioned above, experiments in an SMN-deficient chicken 
DT40 cell line showed that expression of SMN∆7A, but not SMN∆7S, 
rescued cellular proliferation (Cho and Dreyfuss, 2010). These re-
sults suggest that, when stable, SMN∆7 is intrinsically functional. To 
examine SMN∆7A functionality in a more disease-relevant cell type, 
control and SMA-induced pluripotent stem cell (iPSC) motor neuron 
cultures were transduced with lentiviral vectors expressing an 
mCherry control protein or SMN∆7A (Figure 6B). At 4 wk postdif-
ferentiation, no statistical difference was observed between control 
and SMA motor neurons; however, by 6 wk, SMA motor neuron 
numbers had decreased significantly to ∼7% of the total cell popula-
tion (Figure 6B). In contrast, expression of SMN∆7A maintained mo-
tor neuron numbers to approximately the same level as the controls 
and nearly twofold greater than untreated cells (Figure 6B). Thus 
expression of SMN∆7A improves survival of human iPSCs when dif-
ferentiated into motor neuron lineages.
SMNΔ7A is a protective modifier of intermediate SMA 
mouse phenotypes
To examine the importance of the Slmb degron in a mammalian 
organismal system, two previously developed SMA mouse 
models were utilized. As mentioned above, the “Delta7” mouse 
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ligase complex as a novel SMN binding part-
ner whose interaction is conserved in hu-
man. Depletion of Slmb or B-TrCP by RNAi 
resulted in an increase in steady-state SMN 
levels in Drosophila and human cells, respec-
tively. We also showed that ectopic expres-
sion of SMN∆7S270A, but not SMN∆7 or 
SMN∆7S270D, a phosphomimetic, is a protec-
tive modifier of SMA phenotypes in animal 
models and human iPSC cultures.
The SCFSlmb degron is exposed by 
SMN2 exon skipping
A previous study posited that a phosphode-
gron was specifically created by exon 7 skip-
ping and that this event represented a key 
aspect of the SMA disease mechanism (Cho 
and Dreyfuss, 2010). Our identification of a 
putative Slmb binding site located in the C-
terminal self-oligomerization domain of 
Drosophila and human SMN has allowed us 
to explore the molecular details of this 
hypothesis. The mutation of a conserved 
serine within the Slmb degron not only dis-
rupted the interaction between SMN and 
Slmb but also stabilized full-length SMN 
and SMN∆7. Notably, the degron mutation 
has a greater effect on SMN levels (both full-
length and ∆7) when made in the context of 
a protein that does not efficiently self-oligo-
merize. These and other findings strongly 
suggest that the Slmb degron is uncovered 
when SMN is monomeric, whereas it is less 
accessible when SMN forms higher-order 
multimers. On the basis of these results, we 
conclude that SMN2 exon skipping does 
not create a potent protein degradation 
signal; rather, it exposes an existing one.
SMN targeting by multiple E2 and E3 
systems
SMN degradation via the UPS is well estab-
lished (Chang et al., 2004; Burnett et al., 
2009; Kwon et al., 2011). Using candidate 
approaches, investigators have studied 
other E3 ligases that have been reported to 
target SMN for degradation in cultured hu-
man cells (Hsu et al., 2010; Kwon et al., 
2013; Han et al., 2016). Given our findings, 
it is therefore likely that SMN is targeted by 
multiple E3 ubiquitin ligases, as this regula-
tory paradigm has been demonstrated for 
a number of proteins (e.g., p53; Jain and 
Barton, 2010). Targeting of a single protein 
by multiple E3 ligases is thought to provide 
regulatory specificity by expressing the 
appropriate degradation complexes only within certain tissues, sub-
cellular compartments, or developmental time frames. Moreover, 
ubiquitylation does not always result in immediate destruction of 
the target; differential use of ubiquitin lysine linkages or chain length 
can alter a protein’s fate (Mukhopadhyay and Riezman, 2007; Ikeda 
and Dikic, 2008; Liu and Walters, 2010).
isolated factors that copurifiy with SMN from Drosophila embryos 
that exclusively express Flag-SMN. This approach reduces potential 
bias towards SMN partner proteins that may be more abundant in a 
given tissue or cell line (Charroux et al., 1999; Meister et al., 2001; 
Pellizzoni et al., 2002; Kroiss et al., 2008; Trinkle-Mulcahy et al., 2008; 
Guruharsha et al., 2011). Here we identify the SCFSlmb E3 ubiquitin 
FIGURE 6: Stabilization of endogenous SMN and SMN∆7 in cultured human cells. (A) HEK 293T 
cells were transfected with equivalent amounts of GFP-SMN∆7A or -SMN∆7S. The following 
day, cells were harvested after treatment with cycloheximide (CHX) for zero to 10 h. Western 
blotting with anti-SMN showed that SMN∆7S stabilizes endogenous SMN and SMN∆7 to a 
greater extent than SMN∆7A. By comparing band intensities within a given lane, we generated 
average intensity ratios for each time point using replicate blots. We then calculated a 
“stabilization factor” by taking a ratio of these two ratios. The protective benefit of 
overexpressing ∆7S vs. ∆7A at t = 0 h was roughly 3.0× for endogenous SMN∆7 and 1.75× for 
full-length SMN. (B) SMN∆7A (S270A) expression protects SMA iPSC-derived motor neurons. 
Control motor neurons were left untreated or transduced with a lentiviral vector expressing an 
mCherry control. SMA motor neurons were left untreated or transduced with a lentiviral vector 
expressing an mCherry control or a lentiviral vector expressing SMN∆7A (S270A). At 4 wk of 
differentiation, there was no difference in motor neuron survival between control and SMA iPSC 
motor neuron cultures in any of the treatment groups. However, at 6 wk, SMI-32-positive motor 
neurons showed selective loss in SMA iPSC motor neuron cultures in the untreated and 
lenti-mCherry groups compared with control iPSC motor neuron cultures. In contrast, lenti-
SMN∆7A expression fully protects SMA iPSC-derived motor neurons. Representative images of 
control and SMA iPSC-derived motor neurons labeled with SMI-32 (green) and mCherry (red). 
Nuclei are stained with DAPI and shown in blue. *p < 0.05 by ANOVA. NS = not significant. n = 3[AQ 5]
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Avenues of future exploration include determination of the E2 
proteins that partner with SCFSlmb as well as the types of ubiquitin 
lysine chain linkages they add to SMN. These two questions are in-
terconnected, as ubiquitin linkage specificity is determined by the 
E2 (Ye and Rape, 2009). Lysine 48 (K48) linked chains typically result 
in degradation of the targeted protein by the 26S proteasome, 
whereas lysine 63 (K63) linkage is more commonly associated with 
lysosomal degradation and nonproteolytic functions such as endo-
cytosis (Tan et al., 2007; Kirkin et al., 2009; Lim and Lim, 2010). Inter-
estingly, recent work has implicated defects in endocytosis in SMA 
(Custer and Androphy, 2014; Dimitriadi et al., 2016; Hosseinibar-
kooie et al., 2016). It remains to be determined how the ubiquity-
lation status of SMN might intersect with endocytic functions.
Does SMN function as a signaling hub?
In the Flag-SMN pull down, we identified three E2 proteins as po-
tential SMN interacting partners (Figure 1C). Among them, Bend-
less (Ben) is particularly interesting. Ben physically interacts with 
TRAF6, an E3 ligase that functions together with Ube2N/Ubc13/Ben 
in human cells (Kim and Choi, 2017). TRAF6 is an activator of NF-kB 
signaling, and its interaction with SMN is thought to inhibit this ac-
tivity (Kim and Choi, 2017). Notably, Ube2N/Ben heterodimerizes 
with Uev1a to form K63 ubiquitin linkages on target proteins (Ye and 
Rape, 2009; van Wijk and Timmers, 2010; Komander and Rape, 
2012; Marblestone et al., 2013; Zhang et al., 2013). Furthermore, 
Ben-Uev1a is involved in upstream activation of both JNK and IMD 
signaling in Drosophila (Zhou et al., 2005; Paquette et al., 2010). 
Previously, we and others have shown that JNK signaling is dysregu-
lated in animal models of SMA (Garcia et al., 2013, 2016; Genabai 
et al., 2015; Ahmad et al., 2016). Moreover, mutations in all three 
components of SCFSlmb lead to constitutive expression of antimicro-
bial peptides, which are also downstream of the IMD pathway 
(Khush et al., 2002). Together, these findings suggest the interesting 
possibility of SMN functioning as a signaling hub that links the UPS 
[AQ 6]
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FIGURE 7: SMN∆7A is a protective modifier of intermediate SMA 
phenotypes in mice. (A) Mouse genotypes include control 
unaffected Smn2B/+ mice, which have a wild-type Smn allele, 
Smn2B/– (2B/–) mice treated with scAAV9 expressing different 
versions of SMN, and untreated 2B/– mice, which are an 
intermediate mouse model of SMA. 1e11 denotes the viral dose. 
scAAV9-SMN expresses full-length SMN, scAAV9-SMN∆7 expresses 
truncated SMN, scAAV9-SMN∆7S270A expresses truncated SMN with 
the S-to-A change in the degron, and scAAV9-SMN∆7S270D expresses 
truncated SMN with a phosphomimic in the degron. Delivery of 
AAV9-SMN∆7A at P1 significantly extended survival in the 
intermediate 2B/– animals, resulting in 100% of the treated pups 
living beyond 100 d, similar to the results obtained with the 
full-length AAV9-SMN construct. Untreated 2B/– animals lived, on 
average, only 30 d. Mice treated with AAV9-SMN∆7S survived an 
average of 45 d. Mice treated with AAV9 expressing SMN∆7D had 
an average life span equivalent or slightly worse than that of 
untreated 2B/– mice. (B) Average weight (measured over time) of 
the animals used in panel A. AAV9-SMN∆7A treated mice also 
gained significantly more weight than either untreated or AAV-
SMN∆7S-treated animals, nearly achieving the same weight as 
2B/– pups treated with full-length SMN cDNA. (C) Mouse genotypes 
include control unaffected Smn2B/+ mice, which carry a wild-type 
Smn allele, and 2B/– mice treated with scAAV9 expressing different 
versions of SMN. scAAV9-SMN expresses full-length SMN and 
scAAV9-SMN∆7S270A expresses truncated SMN with the S-to-A 
change in the degron. AAV-SMN∆7A-treated animals retained their 
improved strength and gross motor functions at late time points 
(P100), as measured by their ability to splay their legs and maintain 
a hanging position using a modified tube test.
FIGURE 8: Proposed model of SMN as a substrate of SCFSlmb E3 
ubiquitin ligase. Unstable SMN monomers, such as those created in 
SMN∆7, are the primary substrates for degradation. Active oligomers 
of full-length SMN (SMN-FL) and partially active SMN-FL•SMN∆7 
dimers (Praveen et al., 2014; Gupta et al., 2015) would be targeted to 
a lesser extent. SCFSlmb is a multicomponent E3 ubiquitin ligase 
composed of Slmb, SkpA, Cul1, and Roc1 (see the text for details). 
This E3 ligase complex functions together with E1 and E2 proteins in 
the ubiquitin proteasome system (UPS) to tag proteins for 
degradation by linkage to ubiquitin (Ub). Phosphorylation (P) by 
GSK3β and/or another kinase (see the text) is predicted to trigger 
ubiquitylation.
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Figure 4. Y203C, G206S, and G210V were previously published in 
Praveen et al., 2014.
Drosophila embryo protein lysate and mass spectrometry
Drosophila embryos (0–12 h) were collected from Oregon-R control 
and Flag-SMN flies, dechorionated, flash frozen, and stored at 
–80°C. Embryos (approxiately 1gr) were then homogenized on ice 
with a Potter tissue grinder in 5 ml of lysis buffer containing 100 mM 
potassium acetate, 30 mM HEPES–KOH at pH 7.4, 2 mM magne-
sium acetate, 5 mM dithiothreitol (DTT), and protease inhibitor 
cocktail. Lysates were centrifuged twice at 20,000 rpm for 20 min at 
4°C and dialyzed for 5 h at 4°C in Buffer D (HEPES 20 mM, pH 7.9, 
100 mM KCl, 2.5 mM MgCl2, 20% glycerol, 0.5 mM DTT, PMSF 
0.2 mM). Lysates were clarified again by centrifugation at 20,000 
rpm for 20 min at 4°C. Lysates were flash frozen using liquid nitro-
gen and stored at –80°C before use. Lysates were then thawed on 
ice, centrifuged at 20,000 rpm for 20 min at 4°C and incubated with 
rotation with 100 μl of EZview Red Anti-FLAG M2 affinity gel (Sigma) 
for 2 h at 4°C. Beads were washed a total of six times using buffer 
with KCl concentrations ranging from 100 to 250 mM with rotation 
for 1 min at 4°C in between each wash. Finally, Flag proteins were 
eluted 3 consecutive times with one bed volume of elution buffer 
(Tris 20 mM, pH 8, 100 mM KCl, 10% glycerol, 0.5 mM DTT, PMSF 
0.2 mM) containing 250 μg/ml 3XFLAG peptide (sigma). The entire 
eluate was used for mass spectrometry analysis on an Orbitrap Velos 
instrument, fitted with a Thermo Easy-spray 50-cm column.
Tissue culture and transfections
S2 cell lines were obtained from the Drosophila Genome Resource 
Center (Bloomington, IL). S2 cells were maintained in SF900 SFM 
(Life Technologies) supplemented with 1% penicillin/streptomycin 
and filter sterilized. Cells were removed from the flask using a cell 
scraper and passaged to maintain a density of ∼106–107 cells/ml. 
S2 cells were transferred to filter sterilized SF900 SFM (Life Tech-
nologies) without antibiotics prior to transfection with Cellfectin II 
(Invitrogen). Transfections were performed according to Cellfectin II 
protocol in a final volume of 4 ml in a T-25 flask containing 107 cells 
that were plated 1 h before transfection. The total amount of DNA 
used in transfections was 2.5 μg. Human embryonic kidney HEK-
293T and HeLa cells were maintained at 37°C with 5% CO2 in 
DMEM (Life Technologies) supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin (Life Technologies). 
Cells (1 × 106–2 × 106) were plated in T-25 flasks and transiently 
transfected with 1–2 μg of plasmid DNA per flask using Lipo-
fectamine (Invitrogen) or FuGENE HD transfection reagent (Roche 
Applied Science, Indianapolis, IN) according to the manufacturer’s 
protocol. Cells were harvested 24–72 h posttransfection.
For siRNA transections, HeLa cells were plated subconfluently in 
T-25 flasks and transfected with 10 nm of siRNA (gift from Mike 
Emanuele lab) and 17 μl Lipofectamine RNAi MAX (Invitrogen) in 
5 ml total media according to manufacturer’s instructions. After 48 h 
of transfection, cells were harvested. For RNAi in S2 cells using 
dsRNA, 107 cells were plated in each well of a six-well plate in 1 ml 
of media. Cells were treated approximately every 24 h with 10 μg/
ml dsRNA targeted against Slmb, Oskar, or Gaussia Luciferaese (as 
controls) as described in Rogers and Rogers, 2008.
In vitro binding assay
GST and GST-SMN were purified from Escherichia coli. In brief, cells 
transformed with BL21*GST-SMN were grown at 37°C overnight and 
then induced using 1 mM IPTG. Recombinant protein was extracted 





to the JNK and IMD pathways, all of which have been shown to be 
disrupted in SMA.
Phosphorylation of the Slmb degron within SMN
As Slmb is known to recognize phospho-degrons, one of the first 
questions raised by our study concerns the identity of the kinase(s) 
responsible for phosphorylating the degron in SMN. A prime candi-
date is GSK3β (Figure 8), as this kinase recognizes a motif (SxxxS/T; 
Liu et al., 2007; Lee et al., 2013) that includes the degron and ex-
tends N-terminally (262SxxxSxxxSxxxT274, numbering as per human 
SMN). In support of this hypothesis, we identified the Drosophila 
GSK3β orthologue, Shaggy (Sgg), in our SMN pull downs (Figure 
1C). Moreover, GSK3β inhibitors as well as siRNA-mediated knock-
down of GSK3β were shown to increase SMN levels, primarily by 
stabilizing the protein (Makhortova et al., 2011; Chen et al., 2012). 
Finally, GSK3β is also responsible for phosphorylation of a degron in 
β-catenin, a well-characterized SCFSlmb substrate (Liu et al., 2002). 
SMA mice have low levels of UBA1 (E1), ultimately leading to accu-
mulation of β-catenin (Wishart et al., 2014). Pharmacological inhibi-
tion of β-catenin improved neuromuscular pathology in Drosophila, 
zebrafish, and mouse SMA models. β-Catenin had previously been 
shown to regulate motor neuron differentiation and stability by 
affecting synaptic structure and function (Murase et al., 2002; Li 
et al., 2008; Ojeda et al., 2011). β-Catenin also regulates motor 
neuron differentiation by retrograde signaling from skeletal muscle 
(Li et al., 2008). The connections of UBA1 and multiple SCFSlmb sub-
strates to motor neuron health thus places the UPS at the center of 
SMA research interest.
Concluding remarks
In summary, this study identifies conserved factors that regulate 
SMN stability. To our knowledge, this work represents the first time 
that SMN complexes have been purified in the context of an intact 
developing organism. Using this approach, we have demonstrated 
that the SCFSlmb E3 ligase complex interacts with a degron embed-
ded within the self-oligomerization domain of SMN. Our findings 
establish plausible connections to disease-relevant cellular pro-
cesses and signaling pathways. Further, they elucidate a model 
(Figure 8) whereby accessibility of the SMN phosphodegron is regu-
lated by self-multimerization, providing an elegant mechanism for 
balancing functional activity with degradation.
MATERIALS AND METHODS
Fly stocks and transgenes
Oregon-R was used as the wild-type control. The SmnX7 microdele-
tion allele (Chang et al., 2008) was a gift from S. Artavanis-Tsakonis 
(Harvard University, Cambridge, MA). This deficiency removes the 
promoter and the entire SMN coding region, leaving only the final 
44bp of the 3′ UTR. All stocks were cultured on molasses and agar 
at room temperature (24 ± 1°C) in half-pint bottles. The Smn trans-
genic constructs were injected into embryos by BestGene (Chino 
Hills, CA) as described in Praveen et al., 2014. In short, a ∼3 kb frag-
ment containing the entire Smn coding region was cloned from the 
Drosophila genome into the pAttB vector (Bischof et al., 2007). A 3X 
FLAG tag was inserted immediately downstream of the start codon 
of dSMN. Point mutations were introduced into this construct using 
Q5 (NEB) site-directed mutagenesis according to manufacturer’s 
instructions. The basal Smn construct used, vSmn, contained three 
single-amino-acid changes, and the addition of the MGLR motif 
to make fruit fly Smn more similar to the evolutionarily conserved 
vertebrate Smn. Subsequently generated constructs used vSmn 
as a template and consist of the amino acid changes detailed in 
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centrifuging the cells for 10 min at 13,000 at 4°C. Western blotting 
on lysates was performed using standard protocols. Rabbit anti-
dSMN serum was generated by injecting rabbits with purified full-
length dSMN protein (Pacific Immunology Corp, CA) and was 
subsequently affinity purified. For Western blotting, dilutions of 1 in 
2500 for the affinity purified anti-dSMN, 1 in 20,000 (fly) or 1 in 5000 
(human) for anti–α-tubulin (Sigma), 1 in 10,000 for monoclonal anti-
Flag (Sigma), 1 in 1000 for anti-Slmb (gift from Greg Rogers), 1 in 
2500 for anti-human SMN (BD Biosciences), 1 in 1000 for anti–B-
TrCP (gift from MB Major lab), 1 in 10,000 for polyclonal anti-Myc 
(Santa Cruz), and 1 in 2000 for anti-GST (Abcam) were used.
Larval locomotion
Smn control and mutant larvae (73–77 h post–egg laying) were 
placed on a 1.5% agarose molasses tray five at a time. The tray was 
then placed in a box with a camera, and the larvae were recorded 
moving freely for 60 s. Each set of larvae was recorded three times, 
and one video was chosen for analysis based on video quality. The 
videos were then converted to AVI files and analyzed using the 
wrMTrck plug-in of the Fiji software. The “Body Lengths per Sec-
ond” was calculated in wrMTrck by dividing the track length by half 
the perimeter and time (seconds). p Values were generated using a 
multiple comparison analysis of variance (ANOVA).
SMA mouse models
Two previously developed SMA mouse models were utilized. The 
“Delta7” mouse (Smn−/−;SMN2;SMN∆7) is a model of severe SMA 
(Le et al., 2005). The “2B/–“ mouse (Smn2B/–) is a model of interme-
diate SMA (Bowerman et al., 2012; Rindt et al., 2015). Adeno-asso-
ciated virus serotype 9 (AAV9) delivered SMN cDNA isoforms to 
these SMA mice, as previously described (Foust et al., 2010; Passini 
et al., 2010; Valori et al., 2010; Dominguez et al., 2011; Glascock 
et al., 2012). Gross motor function was measured using a modified 
tube test which tests the ability of mice to splay their legs and 
maintain a hanging position.
Human iPSC cell culture
Human iPSCs from two independent unaffected control and two 
SMA patient lines were grown as pluripotent colonies on Matrigel 
substrate (Corning) in Nutristem medium (Stemgent). Colonies were 
then lifted using 1 mg/ml Dispase (Life Technologies) and main-
tained as floating spheres of neural progenitor cells in the neural 
progenitor growth medium Stemline (Sigma) supplemented with 
100 ng/ml human basic fibroblast growth factor (FGF-2; Miltenyi), 
100 ng/ml epidermal growth factor (EGF; Miltenyi), and 5 μg/ml 
heparin (Sigma-Aldrich) in ultra-low attachment flasks. Aggregates 
were passaged using a manual chopping technique as previously 
described (Svendsen et al., 1998; Ebert et al., 2013). To induce mo-
tor neuron differentiation, neural progenitor cells were cultured in 
neural induction medium (1:1 DMEM/F12 [Life Technologies], 1× N2 
Supplement [Life Technologies], 5 μg/ml Heparin [Sigma], 1× Non-
Essential Amino Acids [Life Technologies], and 1× Antibiotic-Anti-
mycotic [Life Technologies]) plus 0.1 μM all-trans retinoic acid (RA) 
for 2 wk; 1 μM Purmorphamine (PMN; Stemgent) was added during 
the second week. Spheres were then dissociated with TrypLE Ex-
press (Life Technologies) and plated onto Matrigel-coated 12-mm 
coverslips in NIM plus 1 μM RA, 1 μM PMN, 1× B27 Supplement 
(Life Technologies), 200 ng/ml ascorbic acid (Sigma), 1 μM cAMP 
(Sigma), 10 ng/ml BDNF (Peprotech), and 10 ng/ml GDNF (Peprot-
ech). One week postplating, cells were infected with lentiviral 
vectors (MOI = 5) expressing mCherry alone or SMN S270A-IRES-






was purchased from Novus Biologicals (cat# H00008945). 
SMN•Gem2 complexes were coexpressed in E. coli using SMN∆5 
and Gemin2(12–280) constructs, as described in Gupta et al. (2015). 
Glutathione sepharose 4B beads were washed 3× with phosphate-
buffered saline (PBS). GST alone, GST-SMN, or GST-B-TrCP1 were 
attached to beads during 4-h-overnight incubation at 4°C in PBS 
with rotation. Beads were then washed 3× with modified RIPA buffer 
(50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM EDTA, 1% NP-40). 
Beads (20 μl) with ∼2 μg attached GST-tagged protein (as deter-
mined by Coomassie stain with BSA standard) were added to 200 μl 
modified RIPA buffer with 100 μg/ml BSA block. SMN•Gem2 (2 μg) 
was added, and the mixture was rotated end over end at 4°C over-
night. Beads were then washed 3× with modified RIPA buffer, and 
10 μl SDS loading buffer was added followed by boiling for 5 min.
In vivo ubiquitylation assay
The in vivo ubiquitylation assay was performed as described previ-
ously (Choudhury et al., 2016). Briefly, HEK-293T cells were trans-
fected as indicated in 10-cm dishes using Lipofectamine2000 
(Thermo Fisher Scientific). The day after, cells were treated with 
20 μM of MG132 for 4 h and then harvested in PBS. Of the cell sus-
pension, 80% was lysed in 6 M guanidine-HCl–containing buffer and 
used to pull down His-Ubiquitinated proteins on Ni2+-NTA beads, 
while the remaining 20% was used to prepare inputs. Ni2+ pull-
down eluates and inputs were separated through SDS–PAGE and 
analyzed by Western blot.
Cycloheximide treatment
Following RNAi treatment, S2 cells were pooled, centrifuged, and 
resuspended in fresh media. One-third of these cells were frozen 
and taken as the 0 h time point. The remainders of the cells were 
replated in six-well plates. Cycloheximide (CHX; 100 μg/ml) was 
added to each sample, and cells were harvested at 2 and 6 h 
following treatment.
Immunoprecipitation
Clarified cell lysates were precleared with immunoglobulin G aga-
rose beads for 1 h at 4°C and again precleared overnight at 4°C. 
The precleared lysates were then incubated with anti-FLAG anti-
body cross-linked to agarose beads (EZview Red Anti-FLAG M2 af-
finity gel, Sigma) for 2 h at 4°C with rotation. The beads were washed 
with lysis buffer or modified lysis buffer six times and boiled in SDS 
gel-loading buffer. Eluted proteins were run on an SDS–PAGE for 
Western blotting.
Antibodies and Western blotting
Larval and adult lysates were prepared by crushing the animals in 
lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% 
NP-40) with 1× (adults) or 10× (larvae) protease inhibitor cocktail 
(Invitrogen) and clearing the lysate by centrifugation at 13,000 rpm 
for 10 min at 4°C. S2 cell lysates were prepared by suspending cells 
in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 
1% NP-40) with 10% glycerol and 1× protease inhibitor cocktail (In-
vitrogen) and disrupting cell membranes by pulling the suspension 
through a 25-gauge needle (Becton Dickinson). The lysate was then 
cleared by centrifugation at 13,000 rpm for 10 min at 4°C. Human 
cells (293T and HeLa) were first gently washed in ice-cold 1× PBS 
and then collected in ice-cold 1× PBS by scraping. Cells were 
pelleted by spinning at 1000 rpm for 5 min. The supernatant was 
removed, and cells were resuspended in ice-cold lysis buffer (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40) and allowed 
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EF1α promoter. Uninfected cells served as controls. Cells were ana-
lyzed at 1 and 3 wk postinfection, which was 4 and 6 wk of total 
differentiation (Ebert et al., 2009; Sareen et al., 2013).
Immunocytochemistry
Coverslips were fixed in 4% paraformaldehyde (Electron Micros-
copy Sciences) for 20 min at room temperature and rinsed with PBS. 
Cells were blocked with 5% normal donkey serum (Millipore) and 
permeabilized in 0.2% Triton X-100 (Sigma) for 30 min at room tem-
perature. Cells were then incubated in primary antibody solution for 
1 h, rinsed with PBS and incubated in secondary antibody solution 
for 1 h at room temperature. Finally, nuclei were labeled with 
Hoechst nuclear stain (Sigma) to label DNA and mounted onto glass 
slides using FluoroMount medium (SouthernBiotech). Primary anti-
bodies used were mouse anti–SMI-32 (Covance SMI-32R; 1:1000) 
and rabbit anti-mCherry (ThermoFisher; 1:1000). Secondary anti-
bodies used were donkey anti-rabbit Cy3 (Jackson Immunoresearch 
711–165–152) and donkey anti-mouse AF488 (Invitrogen A21202).
Immunocytochemical analysis
Images were acquired from five random fields per coverslip using an 
inverted fluorescent microscope (Nikon) and NIS Elements software. 
Images were blinded and manually analyzed for antigen specificity 
with NIS Elements software.
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SMN protein levels inversely correlate with the severity of spinal muscular atrophy. The SCFSlmbE3 ligase complex interacts with a 
degron embedded within the C-terminal self-oligomerization domain of SMN. The findings elucidate a model whereby accessibility of 
the SMN degron is regulated by self-multimerization.
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